Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bright Minds Biosciences (DRUG) Income from Continuing Operations: 2019-2021

Historic Income from Continuing Operations for Bright Minds Biosciences (DRUG) over the last 1 years, with Jun 2021 value amounting to $3.2 million.

  • Bright Minds Biosciences' Income from Continuing Operations rose 18524.75% to $3.2 million in Q2 2021 from the same period last year, while for Jun 2021 it was $4.0 million, marking a year-over-year change of. This contributed to the annual value of -$477,865 for FY2020, which is 1818.26% down from last year.
  • Per Bright Minds Biosciences' latest filing, its Income from Continuing Operations stood at $3.2 million for Q2 2021, which was up 681.59% from $405,879 recorded in Q1 2021.
  • Bright Minds Biosciences' 5-year Income from Continuing Operations high stood at $3.2 million for Q2 2021, and its period low was $17,033 during Q2 2020.
  • Its 3-year average for Income from Continuing Operations is $681,365, with a median of $216,674 in 2020.
  • Data for Bright Minds Biosciences' Income from Continuing Operations shows a peak YoY surged of 18,524.75% (in 2021) over the last 5 years.
  • Bright Minds Biosciences' Income from Continuing Operations (Quarterly) stood at $59,638 in 2019, then skyrocketed by 257.66% to $220,046 in 2020, then surged by 18,524.75% to $3.2 million in 2021.
  • Its Income from Continuing Operations was $3.2 million in Q2 2021, compared to $405,879 in Q1 2021 and $220,046 in Q4 2020.